Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450925 · ClinicalTrials.gov registry record · Phase 2

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

A Phase 2 study of Vitamin D Deficiency and Graft Vs Host Disease, sponsored by Children's Hospital Medical Center, Cincinnati.

Recruiting
Registry status
Phase 2
Development phase
190
Enrollment target
3
Study locations

NCT06450925 is a Phase 2 study of Vitamin D Deficiency and Graft Vs Host Disease that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 190 participants, below the 272-participant average among 48 other Vitamin D Deficiency trials with a reported enrollment target (30% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450925, a Phase 2 study of Vitamin D Deficiency and Graft Vs Host Disease, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.

RECRUITING
Registry status
Phase 2
Development phase
190 participants
Enrollment target
3
Study locations

Study Summary

The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.

Interventions

  • OTHER Placebo
  • DRUG Vitamin A

Study Locations (3)

Florida

  • Moffitt Cancer Center - Tampa

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 190 participants
Start Date 2025-03-25
Est. Completion 2029-08
Phase Phase 2

What the Registry Record Tells You About NCT06450925

The ClinicalTrials.gov registry entry for NCT06450925 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 272-participant average among 48 other Vitamin D Deficiency trials with a reported enrollment target (30% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Vitamin D Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06450925 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT06450925 about?

NCT06450925 is a clinical study titled "Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.". The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.

What is the current status of trial NCT06450925?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2025-03-25. Estimated completion is 2029-08.

What conditions does trial NCT06450925 study?

This clinical trial studies the following conditions: Vitamin D Deficiency, Graft Vs Host Disease, Vitamin A Deficiency.

What interventions are being tested in trial NCT06450925?

The interventions under investigation include: Placebo (OTHER), Vitamin A (DRUG).

Who is sponsoring clinical trial NCT06450925?

This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06450925 being conducted?

This trial has 3 study locations across Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vitamin D Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.